Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Date:10/2/2008

Data Indicate Dual Modes of Action and Synergy with Chemotherapy

DALLAS, Oct. 2 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves. In preclinical models of human breast cancer (MX-1), Angiolix had a significant anti-cancer effect in vivo; this effect was enhanced when Angiolix was given in combination with conventional chemotherapy for breast cancer. The studies were conducted at Imperial College London and presented at the International Conference titled "Realizing the Commercial Potential of Therapeutic Antibodies," held in London, UK.

"We are delighted with these results which demonstrate the substantial anti-cancer effect of Angiolix, which we feel is comparable to Avastin yet achieved through a different and potentially complementary mechanism of action," stated Jeffrey B. Davis, President & CEO. "As stated previously, Access is actively seeking potential partners for the further clinical development of Angiolix."

"Angiolix is highly tumor specific," continued Agamemnon Epenetos, Chief Scientific Officer, Europe, "because the target lactadherin is primarily found in tumors and not in normal tissues. Other targets, such as VEGF, are present in many normal tissues; the blocking of VEGF may contribute to side effects such as high blood pressure and bleeding episodes, for example. Angiolix appears to be a more tumor selective anti-angiogenesis monoclonal antibody, with the benefit of having anti-proliferative activity."

Access is continuing to conduct pre-clinical studies at Imperial College London to more fully define the safety and efficacy profile of Angiolix.

About Angiolix:

Angiolix is a novel humanized monoclonal antibody which has considerable potential for the treatmen
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... in a novel way to design molecules that ... for breast cancer research. Scientists from the Albany ... showed that they were indeed potential anti-breast cancer ... paper detailing the research, Computational Design and Experimental ...
... helps patients with severe depression who don't respond to ... the earlier stages of the illness, according to ... ,"Electroconvulsive therapy has been shown to be a highly ... severe depression, bipolar disorder, and schizophrenia," writes Dr. Stephen ...
... women's separatist outfit, Dukhtaran-e-Milat (DeM) Monday opposed introduction of ... no such plans. ,Addressing a media conference ... oppose tooth and nail the nefarious Indian designs to ... introduction of sex education in schools." ,Andrabi, ...
... obviously thrilled with their landmark discovery of hemangioblasts or ... , According to the company,the stem cells made from ... and arteries of mice and rats, and appear to start ... blood vessel precursor cells out of the stem cells. The ...
... a deadly parasitic disease transmitted by the tiny sand fly. ... the scourge. ,According to C.P. Thakur, a former central ... over 100,000 people, mostly the poor, are suffering from this disease ... dying in thousands and silently. It is unlike when dozens died ...
... of Australia has advised to avoid using cups while feeding ... ,Traditionally, hospitals and parents have used bottles or ... some cases, hospitals have turned to cup feeding, in which ... placed beneath the upper lip. ,Anndrea Flint, a ...
Cached Medicine News:Health News:Researchers Identifies Molecules That is Effective in Fighting Against Breast Cancer 2Health News:Despite Being Effective Electroconvulsive Therapy is Underused for Severe Depression 2Health News:Hemangioblasts Aiding Eye Damage Repair 2Health News:Bihar Under the Grip of Kala Azar 2
... detects the presence of Hemoglobin S ... of reconstituted solubility buffer and 20l of ... cell hemoglobin control. Each test kit contains ... two buffer dispensing caps and two vials ...
... Streck Cytometry Concentrate is for use ... by flow cytometry. Each 70ml bottle of ... fluid with distilled water. Compared to Cubitainers, ... usable space and saves money without compromising ...
... is an assayed control for monitoring immunophenotyping ... accuracy and reproducibility of all the steps ... red blood cell lysis. Reference values for ... B lymphocytes, granulocytes, monocytes, and NK cells. ...
Use Streck-Sheath to count and classify white blood cells on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf life is two years from date of manufacture...
Medicine Products: